Glück Conviction Score™ ⓘ
BLTE
BELITE BIO, INC
⚠
Kein belastbares Signal — erst 31 % der Signal-Gewichte sind mit Daten unterlegt — z. B. junger Filer ohne ausreichende Historie.
Effektiv: Kein belastbares Signal
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
38,6
28 neu, 25 erhöht, 206,0M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 154.17 | -10.4 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 136.76 | +1.0 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 142.76 | EMA50: 150.08 | |
| MACD-Histogramm | Bullisch | 10 % | 0.206 | Bullisch | |
| RSI(14) | Neutral | 10 % | 42.3 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 38.1 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 17.0 | +DI: 12.9 / −DI: 16.2 | |
| Z-Score(60) | Neutral | 5 % | -1.39 | In Range | |
| 52W-Position | Neutral | 5 % | 60.9 % | Hoch 190.30 / Tief 56.81 | |
| Bollinger(20,2σ) | Neutral | 5 % | 27.6 % | Upper 148.39 / Mid 141.32 / Lower 134.26 | |
| LinReg-Slope(60) | Bärisch | 10 % | -0.4785 | R²=0.51 / annualisiert -78.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -226 | 152,45 | -34.453,09 | -68,1% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -9 | 155,25 | -1.397,28 | -2,8% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 154,61 | -463,83 | -0,9% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -428 | 153,56 | -65.725,18 | -129,9% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -100 | 156,00 | -15.600,00 | -30,8% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 151,57 | -1.212,56 | -2,4% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -100 | 155,97 | -15.597,00 | -30,8% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -424 | 152,67 | -64.732,80 | -127,9% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 154,41 | -37.058,81 | -73,2% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -128 | 153,42 | -19.637,54 | -38,8% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -120 | 153,92 | -18.470,60 | -36,5% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -363 | 154,44 | -56.062,92 | -110,8% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -173 | 155,48 | -26.897,54 | -53,2% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -155 | 157,29 | -24.379,90 | -48,2% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -121 | 156,53 | -18.940,03 | -37,4% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -68 | 158,11 | -10.751,48 | -21,3% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -172 | 157,49 | -27.088,35 | -53,5% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -325 | 155,21 | -50.441,95 | -99,7% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -236 | 154,24 | -36.400,05 | -71,9% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -235 | 156,57 | -36.793,41 | -72,7% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -32 | 153,50 | -4.911,84 | -9,7% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -65 | 158,35 | -10.292,62 | -20,3% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -346 | 155,48 | -53.794,70 | -106,3% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -288 | 154,38 | -44.461,35 | -87,9% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -106 | 157,45 | -16.689,89 | -33,0% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -82 | 156,24 | -12.811,80 | -25,3% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -52 | 153,89 | -8.002,50 | -15,8% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -38 | 159,08 | -6.044,98 | -11,9% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -23 | 160,00 | -3.680,00 | -7,3% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -517 | 156,59 | -80.955,27 | -160,0% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -340 | 157,37 | -53.506,38 | -105,8% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -101 | 158,15 | -15.972,68 | -31,6% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -42 | 155,68 | -6.538,42 | -12,9% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -22 | 158,19 | -3.480,27 | -6,9% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -102 | 157,39 | -16.053,36 | -31,7% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -339 | 156,43 | -53.029,91 | -104,8% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -278 | 154,58 | -42.972,68 | -84,9% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -259 | 155,52 | -40.280,41 | -79,6% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 154,65 | -1.855,76 | -3,7% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -380 | 159,42 | -60.579,30 | -119,7% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -222 | 157,49 | -34.962,11 | -69,1% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -120 | 160,27 | -19.232,90 | -38,0% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -89 | 161,72 | -14.393,14 | -28,4% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -62 | 158,71 | -9.840,06 | -19,4% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 162,14 | -8.755,69 | -17,3% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -53 | 156,61 | -8.300,42 | -16,4% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 155,36 | -1.242,87 | -2,5% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -231 | 162,38 | -37.509,20 | -74,1% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -409 | 163,56 | -66.894,94 | -132,2% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 164,07 | -5.906,58 | -11,7% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -280 | 161,62 | -45.253,91 | -89,4% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -44 | 160,83 | -7.076,72 | -14,0% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -74 | 157,86 | -11.681,98 | -23,1% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 162,53 | -487,59 | -1,0% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -28 | 161,22 | -4.514,20 | -8,9% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -190 | 158,65 | -30.142,89 | -59,6% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -330 | 160,40 | -52.931,31 | -104,6% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -375 | 159,46 | -59.797,54 | -118,2% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -158 | 165,38 | -26.129,39 | -51,6% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -127 | 166,56 | -21.153,23 | -41,8% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 168,43 | -9.095,43 | -18,0% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 169,56 | -3.560,69 | -7,0% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -373 | 167,37 | -62.430,61 | -123,4% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -267 | 164,47 | -43.914,40 | -86,8% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -75 | 170,58 | -12.793,75 | -25,3% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -31 | 165,70 | -5.136,73 | -10,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -20 | 166,32 | -3.326,40 | -6,6% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 173,04 | -3.633,86 | -7,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -257 | 171,62 | -44.105,06 | -87,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -249 | 172,49 | -42.950,03 | -84,9% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -141 | 167,42 | -23.606,30 | -46,7% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -105 | 169,52 | -17.799,98 | -35,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -101 | 168,64 | -17.032,19 | -33,7% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -78 | 164,60 | -12.838,85 | -25,4% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -332 | 165,49 | -54.943,84 | -108,6% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -312 | 166,49 | -51.943,57 | -102,7% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -214 | 167,34 | -35.810,46 | -70,8% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -64 | 163,49 | -10.463,67 | -20,7% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -524 | 163,52 | -85.684,11 | -169,4% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -284 | 162,76 | -46.222,48 | -91,4% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -124 | 164,40 | -20.385,71 | -40,3% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -40 | 165,29 | -6.611,74 | -13,1% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -16 | 167,17 | -2.674,64 | -5,3% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -9 | 168,35 | -1.515,15 | -3,0% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 166,91 | -500,72 | -1,0% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -274 | 161,41 | -44.226,12 | -87,4% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -226 | 160,55 | -36.283,71 | -71,7% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 162,48 | -35.096,39 | -69,4% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -200 | 163,33 | -32.665,00 | -64,6% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -52 | 159,38 | -8.287,96 | -16,4% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -32 | 158,46 | -5.070,60 | -10,0% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 164,12 | -1.969,48 | -3,9% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 163,21 | -5.875,60 | -11,6% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 161,61 | -38.786,33 | -76,7% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -219 | 159,81 | -34.999,09 | -69,2% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 158,28 | -34.188,13 | -67,6% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -201 | 160,35 | -32.229,85 | -63,7% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -76 | 162,26 | -12.332,05 | -24,4% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 170,77 | -1.366,12 | -2,7% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -537 | 168,64 | -90.562,04 | -179,0% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -383 | 167,58 | -64.182,83 | -126,9% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -68 | 169,15 | -11.502,36 | -22,7% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -4 | 171,19 | -684,76 | -1,4% | |
| 2026-04-09 | Chen Wan-Shan | Director | Open Market Sale | -1.100 | 180,43 | -198.473,11 | -392,3% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2.000 | 181,40 | -362.790,00 | -717,0% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2.000 | 180,35 | -360.695,00 | -712,9% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -2.500 | 180,36 | -450.894,50 | -891,2% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -1.909 | 182,58 | -348.541,78 | -688,9% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 183,00 | -36.600,00 | -72,3% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -291 | 183,08 | -53.276,66 | -105,3% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3.500 | 181,33 | -634.656,40 | -1254,4% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3.000 | 182,40 | -547.188,00 | -1081,5% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.057.412 | 3.027.704 | 29.708 | 456.104.722 | Aufgestockt | +1,0% | |
| Paradigm Biocapital Advisors LP | 1.114.784 | 0 | 1.114.784 | 177.741.161 | Neu | +100,0% | |
| UBS Group AG | 768.359 | 128.752 | 639.607 | 122.507.159 | Aufgestockt | +496,8% | |
| RTW INVESTMENTS, LP | 715.332 | 715.332 | 0 | 114.052.534 | Unverändert | 0,0% | |
| MILLENNIUM MANAGEMENT LLC | 570.088 | 558.882 | 11.206 | 90.894.831 | Aufgestockt | +2,0% | |
| Holocene Advisors, LP | 494.495 | 84.067 | 410.428 | 78.842.283 | Aufgestockt | +488,2% | |
| RA CAPITAL MANAGEMENT, L.P. | 432.484 | 0 | 432.484 | 69.180.141 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 357.650 | 383.091 | -25.441 | 57.023.716 | Reduziert | -6,6% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 304.013 | 233.813 | 70.200 | 48.471.833 | Aufgestockt | +30,0% | |
| Point72 Asset Management, L.P. | 284.437 | 0 | 284.437 | 45.498.543 | Neu | +100,0% | |
| MORGAN STANLEY | 201.409 | 28.013 | 173.396 | 32.112.649 | Aufgestockt | +619,0% | |
| MARSHALL WACE, LLP | 192.700 | 0 | 192.700 | 30.824.292 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 151.979 | 414.239 | -262.260 | 24.231.532 | Reduziert | -63,3% | |
| Patient Square Capital LP | 116.684 | 0 | 116.684 | 18.604.097 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 105.509 | 44.599 | 60.910 | 16.822.355 | Aufgestockt | +136,6% | |
| MPM BioImpact LLC | 88.045 | 87.760 | 285 | 14.037.895 | Aufgestockt | +0,3% | |
| Affinity Asset Advisors, LLC | 65.000 | 20.000 | 45.000 | 10.363.600 | Aufgestockt | +225,0% | |
| FRED ALGER MANAGEMENT, LLC | 62.574 | 79.394 | -16.820 | 9.976.799 | Reduziert | -21,2% | |
| Western Standard LLC | 60.026 | 0 | 60.026 | 9.601.759 | Neu | +100,0% | |
| PFM Health Sciences, LP | 59.432 | 19.823 | 39.609 | 9.475.838 | Aufgestockt | +199,8% | |
| RENAISSANCE TECHNOLOGIES LLC | 52.000 | 0 | 52.000 | 8.290.880 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 40.354 | 0 | 40.354 | 6.455.026 | Neu | +100,0% | |
| Longaeva Partners L.P. | 33.492 | 0 | 33.492 | 5.339.964 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 33.410 | 0 | 33.410 | 5.326.890 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 32.525 | 2.448 | 30.077 | 5.185.786 | Aufgestockt | +1228,6% | |
| ADAR1 Capital Management, LLC | 26.880 | 39.839 | -12.959 | 4.285.747 | Reduziert | -32,5% | |
| Squadron Capital Management LLC | 26.000 | 0 | 26.000 | 4.158.960 | Neu | +100,0% | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 24.703 | 0 | 24.703 | 3.951.492 | Neu | +100,0% | |
| Quadrature Capital Ltd | 23.708 | 24.832 | -1.124 | 3.780.004 | Reduziert | -4,5% | |
| Aquatic Capital Management LLC | 20.294 | 0 | 20.294 | 3.235.675 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19.600 | 0 | 19.600 | 3.125.024 | Neu | +100,0% | |
| Woodline Partners LP | 18.041 | 0 | 18.041 | 2.885.838 | Neu | +100,0% | |
| Squarepoint Ops LLC | 16.981 | 0 | 16.981 | 2.707.451 | Neu | +100,0% | |
| STATE STREET CORP | 16.048 | 15.740 | 308 | 2.558.693 | Aufgestockt | +2,0% | |
| BANK OF MONTREAL /CAN/ | 15.981 | 15.538 | 443 | 2.548.011 | Aufgestockt | +2,9% | |
| Trexquant Investment LP | 15.072 | 0 | 15.072 | 2.403.080 | Neu | +100,0% | |
| XTX Topco Ltd | 15.058 | 0 | 15.058 | 2.400.848 | Neu | +100,0% | |
| BALANCE CAPITAL PARTNERS L.P. | 14.500 | 0 | 14.500 | 2.311.880 | Neu | +100,0% | |
| Exome Asset Management LLC | 14.328 | 0 | 14.328 | 2.291.907 | Neu | +100,0% | |
| Verdad Advisers, LP | 13.813 | 0 | 13.813 | 2.202.345 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 12.222 | 32.318 | -20.096 | 1.948.676 | Reduziert | -62,2% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 11.897 | 0 | 11.897 | 1.903.044 | Neu | +100,0% | |
| Blackstone Inc. | 10.692 | 0 | 10.692 | 1.704.732 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 10.427 | 10.445 | -18 | 1.662.480 | Reduziert | -0,2% | |
| STEMPOINT CAPITAL LP | 9.163 | 0 | 9.163 | 1.465.713 | Neu | +100,0% | |
| Seven Fleet Capital Management LP | 9.161 | 0 | 9.161 | 1.465.394 | Neu | +100,0% | |
| HighVista Strategies LLC | 8.033 | 0 | 8.033 | 1.280.781 | Neu | +100,0% | |
| Voleon Capital Management LP | 7.883 | 0 | 7.883 | 1.256.866 | Neu | +100,0% | |
| BARCLAYS PLC | 6.822 | 4.176 | 2.646 | 1.087.700 | Aufgestockt | +63,4% | |
| WELLINGTON MANAGEMENT GROUP LLP | 6.198 | 0 | 6.198 | 991.432 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.057.412 | 3.027.704 | +1,0% | 456.104.722 | 33,68 |
| Paradigm Biocapital Advisors LP | 1.114.784 | 0 | +100,0% | 177.741.161 | 13,13 |
| UBS Group AG | 768.359 | 128.752 | +496,8% | 122.507.159 | 9,05 |
| RTW INVESTMENTS, LP | 715.332 | 715.332 | 0,0% | 114.052.534 | 8,42 |
| MILLENNIUM MANAGEMENT LLC | 570.088 | 558.882 | +2,0% | 90.894.831 | 6,71 |
| Holocene Advisors, LP | 494.495 | 84.067 | +488,2% | 78.842.283 | 5,82 |
| EVENTIDE ASSET MANAGEMENT, LLC | 357.650 | 383.091 | -6,6% | 57.023.716 | 4,21 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 304.013 | 233.813 | +30,0% | 48.471.833 | 3,58 |
| MORGAN STANLEY | 201.409 | 28.013 | +619,0% | 32.112.649 | 2,37 |
| PERCEPTIVE ADVISORS LLC | 151.979 | 414.239 | -63,3% | 24.231.532 | 1,79 |
| Patient Square Capital LP | 116.684 | 0 | +100,0% | 18.604.097 | 1,37 |
| GOLDMAN SACHS GROUP INC | 105.509 | 44.599 | +136,6% | 16.822.355 | 1,24 |
| MPM BioImpact LLC | 88.045 | 87.760 | +0,3% | 14.037.895 | 1,04 |
| Affinity Asset Advisors, LLC | 65.000 | 20.000 | +225,0% | 10.363.600 | 0,77 |
| FRED ALGER MANAGEMENT, LLC | 62.574 | 79.394 | -21,2% | 9.976.799 | 0,74 |
| PFM Health Sciences, LP | 59.432 | 19.823 | +199,8% | 9.475.838 | 0,70 |
| RENAISSANCE TECHNOLOGIES LLC | 52.000 | 0 | +100,0% | 8.290.880 | 0,61 |
| Longaeva Partners L.P. | 33.492 | 0 | +100,0% | 5.339.964 | 0,39 |
| TD ASSET MANAGEMENT INC | 33.410 | 0 | +100,0% | 5.326.890 | 0,39 |
| BNP PARIBAS FINANCIAL MARKETS | 32.525 | 2.448 | +1228,6% | 5.185.786 | 0,38 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 74 | 9,3 | 1.380 |
| 31.12.2025 | ✓ | 68 | 7,3 | 1.168 |
| 30.09.2025 | ✓ | 34 | 2,3 | 171 |
| 30.06.2025 | ✓ | 18 | 0,1 | 5 |
| 31.03.2025 | ✓ | 18 | 0,3 | 10 |
| 31.12.2024 | ✓ | 22 | 0,3 | 19 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Darwin Global Management, Ltd. | 3.027.704 | 486.915.357 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 233.813 | 37.400.727 |
| MPM BioImpact LLC | 87.760 | 14.038.090 |
| Holocene Advisors, LP | 84.067 | 13.447.357 |
| FRED ALGER MANAGEMENT, LLC | 79.394 | 12.699.864 |
| Western Standard LLC | 60.026 | 9.601.759 |
| ADAR1 Capital Management, LLC | 39.839 | 6.372.646 |
| JANE STREET GROUP, LLC | 32.318 | 5.169.587 |
| Squadron Capital Management LLC | 26.000 | 4.158.960 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 24.703 | 3.951.492 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 558.882 | 538.141 | +2594.6 % | 89.398.765 |
| RTW INVESTMENTS, LP | 715.332 | 402.832 | +128.9 % | 114.424.507 |
| PERCEPTIVE ADVISORS LLC | 414.239 | 364.451 | +732.0 % | 66.261.670 |
| Point72 Asset Management, L.P. | 284.437 | 281.337 | +9075.4 % | 45.498.543 |
| EVENTIDE ASSET MANAGEMENT, LLC | 383.091 | 187.779 | +96.1 % | 61.279.236 |
| UBS Group AG | 128.752 | 117.418 | +1036.0 % | 20.595.170 |
| GOLDMAN SACHS GROUP INC | 44.599 | 40.893 | +1103.4 % | 7.134.056 |
| MORGAN STANLEY | 28.013 | 22.783 | +435.6 % | 4.480.960 |
| Quadrature Capital Ltd | 24.832 | 21.002 | +548.4 % | 3.972.127 |
| AMERIPRISE FINANCIAL INC | 13.221 | 10.190 | +336.2 % | 2.114.832 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 432.484 | -442.516 | -50.6 % | 69.180.141 |
| Soleus Capital Management, L.P. | 40.354 | -169.646 | -80.8 % | 6.455.026 |
| JPMORGAN CHASE & CO | 3 | -9.806 | -100.0 % | 480 |
| BNP PARIBAS FINANCIAL MARKETS | 2.448 | -9.101 | -78.8 % | 391.582 |
| CITADEL ADVISORS LLC | 5.055 | -5.772 | -53.3 % | 808.598 |
| GEODE CAPITAL MANAGEMENT, LLC | 10.445 | -5.180 | -33.2 % | 1.670.782 |
| China Universal Asset Management Co., Ltd. | 500 | -4.500 | -90.0 % | 79.980 |
| CITIGROUP INC | 2.137 | -1.873 | -46.7 % | 341.835 |
| EverSource Wealth Advisors, LLC | 1.598 | -108 | -6.3 % | 255.616 |
| SBI Securities Co., Ltd. | 50 | -2 | -3.8 % | 7.998 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 14.05.2026 | Yu-Hsin Lin | Passiv (13G/A) | 3,10 % | 1.253.935 | -4,00 pp | |
| 17.02.2026 | Darwin Global Management, Ltd. | Passiv (13G/A) | 8,10 % | 3.027.704 | +1,10 pp | |
| 17.02.2026 | Trehan Abhishek | Passiv (13G/A) | 8,10 % | 3.027.704 | Neu | |
| 17.02.2026 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 7,80 % | 2.928.575 | +1,10 pp | |
| 10.12.2025 | Dr. Abhishek Trehan | Passiv (13G) | 7,00 % | 2.617.094 | Neu | |
| 10.12.2025 | Darwin Global Master Fund, Ltd. | Passiv (13G) | 6,70 % | 2.527.589 | Neu | |
| 10.12.2025 | Darwin Global Management, Ltd. | Passiv (13G) | 7,00 % | 2.617.094 | Neu | |
| 21.01.2025 | Yu-Hsin Lin | Passiv (13G) | 7,10 % | 2.287.070 | Neu | |
| 21.01.2025 | Lin Bioscience International Ltd. | Passiv (13G) | 53,70 % | 17.095.263 | Neu |
Stammdaten
Belite Bio, Inc. ist ein Biopharmaunternehmen in klinischer Phase, das sich auf die Entdeckung und Weiterentwicklung neuartiger Therapien konzentriert. Die primären therapeutischen Bereiche des Unternehmens umfassen atrophische altersbedingte Makuladegeneration und autosomal-rezessive Stargardt-Krankheit. Sein Flaggschiff-Arzneimittelkandidat, LBS-008, ist ein experimentelles orales Medikament, das einmal täglich verabreicht wird. Derzeit in Phase-3-Klinischen Versuchen, ist LBS-008 entwickelt, um die Vitamin-A-Abgabe zum Auge zu modulieren und dadurch die Ansammlung schädlicher Vitamin-A-Metaboliten in Augengeweben zu verhindern. Darüber hinaus entwickelt Belite Bio LBS-009, eine orale Anti-Retinol-Bindeprotein-4-Therapie, in der präklinischen Entwicklung. Diese Therapie zielt auf verschiedene Lebererkrankungen ab, einschließlich nicht-alkoholischer Fettlebererkrankung, nicht-alkoholischer Steatohepatitis und Typ-2-Diabetes. Das 2016 gegründete Unternehmen Belite Bio, Inc. hat seinen Hauptsitz in San Diego, Kalifornien, und funktioniert als Tochterunternehmen von Lin Bioscience International Ltd.
Unternehmen & Branche
| Name | BELITE BIO, INC |
|---|---|
| Ticker | BLTE |
| CIK | 0001889109 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 07782B104 |
|---|---|
| ISIN | US07782B1044 |
| Typ | ADR |
| Marktkapitalisierung | 5,52 Mrd. USD |
| Beta | -1,15 |
| Dividendenrendite | 0,00 % |
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-16 | 500 | 168,76 | 84.380 |
| 2026-04-08 | 5 | 169,79 | 849 |
| 2026-04-02 | 540 | 167,25 | 90.315 |
| 2026-03-26 | 879 | 155,04 | 136.280 |
| 2026-03-25 | 869 | 150,83 | 131.071 |
| 2026-03-19 | 371 | 161,34 | 59.857 |
| 2026-03-18 | 253 | 161,41 | 40.837 |
| 2026-03-16 | 261 | 164,11 | 42.833 |
| 2026-03-13 | 371 | 169,55 | 62.903 |
| 2026-03-10 | 1.360 | 179,12 | 243.603 |
| 2026-03-06 | 109 | 172,57 | 18.810 |
| 2026-03-05 | 4.392 | 177,79 | 780.854 |
| 2026-03-04 | 18.703 | 167,88 | 3.139.860 |
| 2026-03-03 | 4.099 | 177,58 | 727.900 |
| 2026-03-02 | 238 | 190,30 | 45.291 |
| 2026-02-27 | 373 | 188,55 | 70.329 |
| 2026-02-17 | 1 | 175,26 | 175 |
| 2026-02-09 | 2 | 187,86 | 376 |
| 2026-01-26 | 6.935 | 164,58 | 1.141.362 |
| 2026-01-12 | 1.665 | 158,36 | 263.669 |
| 2026-01-05 | 65 | 159,27 | 10.353 |
| 2025-12-31 | 6.244 | 160,82 | 1.004.160 |
| 2025-12-23 | 4.302 | 155,49 | 668.918 |
| 2025-12-22 | 2.370 | 156,00 | 369.720 |
| 2025-12-17 | 2.909 | 149,13 | 433.819 |
| 2025-12-16 | 306 | 142,53 | 43.614 |
| 2025-12-15 | 456 | 141,32 | 64.442 |